vimarsana.com

அரவிந்தோ பார்மா லிமிடெட் ஆன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aurobindo Pharm: Aurobindo Pharma says Rs 420 crore deal to acquire 51 per cent in Cronus Pharma cancelled

Aurobindo Pharm: Aurobindo Pharma says Rs 420 crore deal to acquire 51 per cent in Cronus Pharma cancelled
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.

Andhra pradeshAurobindo pharmaCronus pharma specialities india pvt ltdAurobindo pharma ltd onCentre for veterinary medicineAurobindo pharma ltdHyderabad based cronusVeterinary medicineஆந்திரா பிரதேஷ்அரவிந்தோ பார்மாஅரவிந்தோ பார்மா லிமிடெட் ஆன்மையம் க்கு கால்நடை மருந்துஅரவிந்தோ பார்மா லிமிடெட்கால்நடை மருந்து

Aurobindo Pharma cancels Rs 420 cr deal to acquire 51% stake in Cronus Pharma

Aurobindo Pharma cancels Rs 420 cr deal to acquire 51% stake in Cronus Pharma
businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.

Andhra pradeshAurobindo pharmaCronus pharma specialities india pvt ltdAurobindo pharma ltd onCentre for veterinary medicineAurobindo pharma ltdHyderabad based cronusVeterinary medicineஆந்திரா பிரதேஷ்அரவிந்தோ பார்மாஅரவிந்தோ பார்மா லிமிடெட் ஆன்மையம் க்கு கால்நடை மருந்துஅரவிந்தோ பார்மா லிமிடெட்கால்நடை மருந்து

Aurobindo Pharma To Produce And Market COVAXX s Covid-19 Vaccine for India, UNISEF

Coronavirus vaccine: India could approve emergency use of vaccines made by Pfizer and Bharat Biotech. Aurobindo Pharma Ltd on Thursday said it would make and sell US-based COVAXX s Covid-19 vaccine candidate for supply in India and to the United Nations Children s Fund (UNICEF) under a licensing deal. The Indian pharmaceutical company also has non-exclusive rights to sell the shot, which is currently undergoing an early-stage trial, in certain other emerging markets, the Hyderabad-based company said in an exchange filing. COVAXX, a unit of privately-owned United Biomedical Inc, plans to pursue mid- and late-stage trials for the vaccine candidate from early 2021 in Asia, Latin America and the US.

Andhra pradeshUnited statesOxford astrazenecaAurobindo pharmaUnited nations children fundAurobindo pharma ltd onUnited biomedical incBombay stock exchangeAurobindo pharma to make and sellPharma ltdUnited nations childrenLatin americaBombay stockஆந்திரா பிரதேஷ்ஒன்றுபட்டது மாநிலங்களில்அரவிந்தோ பார்மா

vimarsana © 2020. All Rights Reserved.